局部晚期乳腺癌患者病灶可检测性提高——动态全身[18F]FDG PET/CT先导研究
该前瞻性先导研究纳入10例局部晚期乳腺癌女性,比较动态全身[18F]FDG PET/CT生成的MRFDG参数图像与常规SUV图像的病灶可检测性。MRFDG图像的目标-本底比值是SUV图像的2.28倍(95%CI 2.04-2.54),对比噪声比是SUV图像的1.23倍(95%CI 1.12-1.35);视觉评估在MRFDG图像额外发现3个可疑病灶。作者认为MRFDG图像在局部晚期乳腺癌中较常规SUV图像有提高病灶可检测性的潜力,需在更大队列中进一步验证。
要点
- MRFDG图像目标-本底比值是SUV图像的2.28倍(95%CI 2.04-2.54)。
- MRFDG图像对比噪声比是SUV图像的1.23倍(95%CI 1.12-1.35)。
- 视觉评估在MRFDG图像较SUV图像额外发现3个可疑病灶:腋窝淋巴结、胸骨旁淋巴结、骨盆骨各1个。
核心结论
- 动态全身[18F]FDG PET/CT的MRFDG图像在局部晚期乳腺癌中较常规SUV图像显示出提高病灶可检测性的潜力。
- 作者指出需在更大队列中进一步验证。
研究设计与样本
- 前瞻性先导研究,纳入10例因诊断评估转诊行[18F]FDG PET/CT的局部晚期乳腺癌女性。
- 所有患者接受动态全身[18F]FDG PET/CT:注射示踪剂时开始胸部区域6分钟单床位动态扫描,随后64分钟动态全身PET扫描含16次连续床运动通过,最后行增强CT扫描并生成MRFDG参数图像。
- 病灶可见性通过肿瘤-本底比值和对比噪声比评估,感兴趣体积以SUVmax的50%为固定限值等轮廓勾画肿瘤,本底体积置于肿瘤邻近区域。
- 由5名影像学专家对图像进行视觉评估。
主要发现
- 病灶可见性在MRFDG图像中最佳,目标-本底值是SUV图像目标-本底值的2.28倍(95%CI 2.04-2.54)。
- MRFDG图像的对比噪声值是SUV图像对比噪声值的1.23倍(95%CI 1.12-1.35)。
- 5名影像学专家视觉评估在MRFDG图像较SUV图像额外发现3个可疑病灶:1个可疑腋窝淋巴结、1个可疑胸骨旁淋巴结、1个位于骨盆骨的可疑病灶。
关键数值与推荐
- MRFDG图像目标-本底值较SUV图像高2.28倍(95%CI 2.04-2.54)。
- MRFDG图像对比噪声值较SUV图像高1.23倍(95%CI 1.12-1.35)。
- 视觉评估额外发现3个可疑病灶(腋窝淋巴结、胸骨旁淋巴结、骨盆骨各1个)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出需在更大队列中进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Accurate diagnosis of axillary lymph node (ALN) metastases is essential for prognosis and treatment planning in breast cancer. Evaluation of ALN is done by ultrasound, which is limited by inter-operator variability, and by sentinel lymph node biopsy and/or ALN dissection, none of which are without risks and/or long-term complications. It is known that conventional 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) positron emission tomography/computed tomography (PET/CT) has limited sensitivity for ALN metastases. However, a recently developed dynamic whole-body (D-WB) [18F]FDG PET/CT scanning protocol, allowing for imaging of tissue [18F]FDG metabolic rate (MRFDG), has been shown to have the potential to increase lesion detectability. The study purpose was to examine detectability of malignant lesions in D-WB [18F]FDG PET/CT compared to conventional [18F]FDG PET/CT. RESULTS: This study prospectively included ten women with locally advanced breast cancer who were referred for an [18F]FDG PET/CT as part of their diagnostic work-up. They all underwent D-WB [18F]FDG PET/CT, consisting of a 6 min single bed dynamic scan over the chest region started at the time of tracer injection, a 64 min dynamic WB PET scan consisting of 16 continuous bed motion passes, and finally a contrast-enhanced CT scan, with generation of MRFDG parametric images. Lesion visibility was assessed by tumor-to-background and contrast-to-noise ratios using volumes of interest isocontouring tumors with a set limit of 50% of SUVmax and background volumes placed in the vicinity of tumors. Lesion visibility was best in the MRFDG images, with target-to-background values 2.28 (95% CI: 2.04-2.54) times higher than target-to-background values in SUV images, and contrast-to-noise values 1.23 (95% CI: 1.12-1.35) times higher than contrast-to-noise values in SUV images. Furthermore, five imaging experts visually assessed the images and three additional suspicious lesions were found in the MRFDG images compared to SUV images; one suspicious ALN, one suspicious parasternal lymph node, and one suspicious lesion located in the pelvic bone. CONCLUSIONS: D-WB [18F]FDG PET/CT with MRFDG images show potential for improved lesion detectability compared to conventional SUV images in locally advanced breast cancer. Further validation in larger cohorts is needed. CLINICAL TRIAL REGISTRATION: The trial is registered in clinicaltrials.gov, NCT05110443, https://www. CLINICALTRIALS: gov/study/NCT05110443?term=NCT05110443&rank=1 .
引用
- Pedersen MA, Dias AH, Hjorthaug K, et al. Increased lesion detectability in patients with locally advanced breast cancer-A pilot study using dynamic whole-body [18F]FDG PET/CT. EJNMMI Res. 2024. PMID: 38528239. doi:10.1186/s13550-024-01096-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。